UBS Maintains a 'Neutral' on Impax Laboratories (IPXL); Getting Ready for a Busy Year Ahead
Tweet
Share
E-mailGet Alerts IPXL Hot Sheet
Price: $18.30 --0%
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 15 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS maintains a 'Neutral' on Impax Laboratories (NASDAQ: IPXL) price target raised from $21 to $24.
UBS analyst says, "What’s new? What we learned from the conference call: (1) Mgt. is hopeful of resolution of Adderall XR’s supply situation with the trial starting on April 10th. (2) 11 ANDAs were filed in 2011 (incl. 2 FTM and 1 FTF) and 10 filings planned for 2012. (3) 8 launches expected in 2012 most of which are small para III opportunities with brand sales <$100M; this is subject to lifting of the warning letter and FDA approval. (4) IPX-066’s PDUFA date set for Oct 21st. (5) Busi. dev. efforts remain active. Impax ended the year with a strong cash and AR bal. of $345M and $154M, respectively...Thoughts on the stock: Upcoming catalysts could drive momentum."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $23.62 yesterday.
UBS analyst says, "What’s new? What we learned from the conference call: (1) Mgt. is hopeful of resolution of Adderall XR’s supply situation with the trial starting on April 10th. (2) 11 ANDAs were filed in 2011 (incl. 2 FTM and 1 FTF) and 10 filings planned for 2012. (3) 8 launches expected in 2012 most of which are small para III opportunities with brand sales <$100M; this is subject to lifting of the warning letter and FDA approval. (4) IPX-066’s PDUFA date set for Oct 21st. (5) Busi. dev. efforts remain active. Impax ended the year with a strong cash and AR bal. of $345M and $154M, respectively...Thoughts on the stock: Upcoming catalysts could drive momentum."
For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.
Shares of Impax Laboratories closed at $23.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
- New Street Research Upgrades Micron Technology (MU) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
